Renalytix RNLXY

Renalytix plc focuses on developing and commercializing AI-enabled diagnostic tools for kidney disease management. The company's primary activity centers on its flagship product, kidneyintelX.dkd, an FDA-authorized in vitro prognostic test that uses artificial intelligence to assess the risk of progressive decline in kidney function for patients with Type 2 diabetes and early-stage chronic kidney disease. Renalytix operates in the healthcare diagnostics industry, specifically targeting chronic kidney disease prevention through early risk stratification to enable timely clinical intervention.

Renalytix generates revenue primarily through the sale of kidneyintelX.dkd testing services to healthcare systems and insurance payors that cover patient testing under established reimbursement policies. The company earns income by performing diagnostic tests in its New York City laboratory and billing for each test administered, with Medicare establishing a price of $950 per test following a Local Coverage Determination effective August 1, 2024. Revenue is derived from partnerships with regional healthcare providers who order the test for eligible diabetic chronic kidney disease patients, supporting a business model built on diagnostic service delivery and third-party payer reimbursement.

The company operates through the following segments:

• KidneyIntelX Technology Platform: This segment encompasses the development and commercialization of AI-driven diagnostic solutions derived from licensed intellectual property with Mount Sinai Health System and Joslin Diabetes Center. The platform supports the creation of prognostic tests like kidneyintelX.dkd through proprietary algorithms analyzing blood biomarkers. It includes ongoing research to expand the technology's utility across broader kidney disease populations and clinical settings.
• Clinical Testing Services: This segment involves the operation of Renalytix's certified laboratory that performs kidneyintelX.dkd tests for patients under physician order. The service includes sample processing, AI-driven analysis, result reporting, and compliance with clinical and regulatory standards. The segment enables the company to deliver its diagnostic product directly to healthcare providers and manage end-to-end test fulfillment.

Renalytix occupies a specialized position in the preventive diagnostics market for chronic kidney disease, competing with traditional laboratory tests and emerging biomarker-based assays but differentiating itself through FDA authorization and AI integration. Its competitive advantage stems from being the first to market with an AI-enabled prognostic test specifically validated for predicting kidney function decline in diabetic patients, supported by proprietary technology licensed from leading medical institutions. The company benefits from established reimbursement pathways, including Medicare coverage, which enhances accessibility and adoption compared to purely experimental or self-pay diagnostic alternatives.

Renalytix serves patients with Type 2 diabetes and Stage 1-3b chronic kidney disease who are referred by physicians managing diabetic kidney disease risk. The company's customers include healthcare systems, physician practices, and insurance payors that facilitate access to testing for these patient populations through established clinical workflows and coverage policies. Reimbursement arrangements with entities such as Medicare Administrative Contractors enable broader patient access to the kidneyintelX.dkd test under approved indications.